TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05256966

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sauna (steam)
Description: Steam Sauna
Study: NCT05922904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin
Description: Given by IV (vein)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin
Description: Given by IV (vein)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin
Description: Given by IV (vein)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given by IV (vein)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given by IV (vein)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given by IV (vein)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given by IV (vein)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given by IV (vein)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given by IV (vein)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine
Description: Given by IV (vein)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine
Description: Given by IV (vein)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine
Description: Given by IV (vein)
Study: NCT06511193

Intervention type: DRUG
Intervention: Budenoside/Glycopyrronium/Formoterol
Description: Patients with COPD who initiate BGF as prescribed by physician per the approved country-specific label and reimbursement criteria
Study: NCT05410496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir Alafenamide 25 MG
Description: To assess the safety, efficacy, and drug adherence improvement of TAF switching therapy in kidney or liver transplant patients with HBV infection.
Study: NCT05528510

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab Dose 1
Description: Guselkumab (Dose 1) will be administered as SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab Dose 1
Description: Guselkumab (Dose 1) will be administered as SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab Dose 2
Description: Guselkumab (Dose 2) will be administered as SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab Dose 3
Description: Guselkumab (Dose 3) will be administered as SC injection.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered as SC injection.
Study: NCT05483933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Liposomal Doxorubicin + SL-172154
Description: The investigational product, SL-172154, is a novel fusion protein consisting of human SIRPα and CD40L (SIRPα -Fc-CD40L) linked via a human Fc.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirvetuximab + SL-172154
Description: The investigational product, SL-172154, is a novel fusion protein consisting of human SIRPα and CD40L (SIRPα -Fc-CD40L) linked via a human Fc.
Study: NCT05283980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.25% Bupivacaine
Description: The intervention group/ bupivacaine group will receive up to 25 ml of 0.25% bupivacaine hydrochloride for the Pecs block in comparison to the control group that would receive 0.9% normal saline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.25% Bupivacaine
Description: The intervention group/ bupivacaine group will receive up to 25 ml of 0.25% bupivacaine hydrochloride for the Pecs block in comparison to the control group that would receive 0.9% normal saline
Study: NCT05467904

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Xltranplus, Xltran
Description: Xltranplus and Xltran are full hemp flower formulations

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Xltranplus, Xltran
Description: Xltranplus and Xltran are full hemp flower formulations

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Xltranplus, Xltran
Description: Xltranplus and Xltran are full hemp flower formulations
Study: NCT04755413

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical/Behavioral therapy
Description: * Sedentary lifestyle: Advise increasing exercise to at least 30 minutes of moderate-intensity aerobic activity 5 days a week.~* Overweight/Obese: Advise calorie reduction, dietician consultation.~* Smoking: standard smoking cessation advice and literature and medical therapy as indicated to include Wellbutrin, nicotine patch etc.~* High LDL cholesterol: a) Start high dose statin if patient not on high dose statin.~  b) If on high dose statin, add ezetimibe 10mg daily c) If statin intolerant, start ezetimibe 10mg, colestid or other bile sequestrant combination.~  d) If still not at goal, start PCSK-9 inhibitor e) LDL cut off of \<55mg/dl in diabetes~* Blood Pressure optimization treatment following 2020 International Society of Hypertension Global Hypertension Practice Guidelines.~* Diabetes management: HbA1c goal 6.5%

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Participants will receive standard of care therapy prescribed by their primary care physician and/or cardiologist.

Intervention type: OTHER
Group type: OTHER
Intervention: Registry
Description: Participants with BRS of 0 will get measurements of BRS at the time-points specified for the randomized subjects and also for adverse events.
Study: NCT04286789

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose ORTD-1
Description: Once weekly, single subcutaneous injection of ORTD-1 at a volume of 0.45 mL. Six weekly treatments; 28-day follow-up period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Low dose vehicle control
Description: Once weekly subcutaneous injection of vehicle at a volume of 0.45 mL. Six weekly treatments; 28-day follow-up period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose ORTD-1
Description: Two subcutaneous injections of ORTD-1 at two injection sites once weekly; 0.90 mL of ORTD-1 per each subcutaneous injection. Six weekly treatments; 28-day follow-up period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: High dose vehicle control
Description: Two subcutaneous injections of vehicle at two injection sites once weekly; 0.90 mL of vehicle per each subcutaneous injection. Six weekly treatments; 28-day follow-up period.
Study: NCT06647810

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 690517 formulation 1
Description: BI 690517 formulation 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 690517 formulation 1
Description: BI 690517 formulation 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 690517 formulation 1
Description: BI 690517 formulation 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 690517 formulation 2
Description: BI 690517 formulation 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 690517 formulation 2
Description: BI 690517 formulation 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 690517 formulation 2
Description: BI 690517 formulation 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probenecid
Description: Probenecid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probenecid
Description: Probenecid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probenecid
Description: Probenecid
Study: NCT04696263

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Da Vinci ® Xi system - MP Robotic Radical Prostatectomy
Description: After pneumoperitoneum is established, four 8mm, one 12 mm, and one 5 mm trocars are placed for instrumentation. After the robot is docked, radical prostatectomy is performed with the SOC approach.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Da Vinci ® SP system - SP Robotic Radical Prostatectomy
Description: After induction of general anesthesia and supine participant positioning, a 3.5 cm infraumbilical incision will be made for single-port access into the space of Retzius. Radical prostatectomy is then performed with the SOC approach
Study: NCT04649476

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: The participants will receive camrelizumab (200 mg) intravenous infusion each 2-week cycle for 3 cycles prior to surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumanb plus TPF
Description: The participants will receive camrelizumab (200 mg) through intravenous infusion each 2-week cycle, and docetaxel (T) 75 mg/m2, cisplatin (P) 75 mg/m2, 5-Fluorouracil (F) 750 mg/m2 through intravenous infusion each 3-week cycle for 2 cycles.
Study: NCT05166499

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxy Methyl Butyrate
Description: Hydroxy Methyl Butyrate

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Balanced Amino Acids
Description: Balanced Amino Acids
Study: NCT06285318

Intervention type: OTHER
Intervention: Teclistamab
Description: No Intervention will be administered during the study. Retrospective data analysis using participants medical records collected within this study will be entered into CRF.

Intervention type: OTHER
Intervention: Teclistamab
Description: No Intervention will be administered during the study. Retrospective data analysis using participants medical records collected within this study will be entered into CRF.

Intervention type: OTHER
Intervention: Talquetamab
Description: No Intervention will be administered during the study. Retrospective data analysis using participants medical records collected within this study will be entered into CRF.
Study: NCT06422273

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: Endobronchial (topical) tranexamic acid used prophylactically prior to performing transbronchial biopsies in lung transplant recipients

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline (placebo)
Description: Topical Saline (placebo) administered as endobronchial topical application prior to performing transbronchial biopsies in lung transplant recipients.
Study: NCT04675788

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: Subjects will receive oral progesterone 400 mg (two x 200 mg capsules) once daily every evening for 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ibutilide
Description: Ibutilide 0.003 mg/kg administered to all subjects to modestly lengthen the QT interval

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibutilide
Description: Ibutilide 0.003 mg/kg administered to all subjects to modestly lengthen the QT interval

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ibutilide
Description: Ibutilide 0.003 mg/kg administered to all subjects to modestly lengthen the QT interval

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibutilide
Description: Ibutilide 0.003 mg/kg administered to all subjects to modestly lengthen the QT interval

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone
Description: Subjects will apply transdermal testosterone gel once daily every morning for 3 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lactose capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lactose capsules
Study: NCT05652335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-79635322
Description: JNJ-79635322 will be administered as SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-79635322
Description: JNJ-79635322 will be administered as SC injection.
Study: NCT05116241

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BPZE1 pertussis vaccine and placebo
Description: Live attenuated pertussis vaccine and placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BPZE1 pertussis vaccine and Boostrix
Description: Live attenuated pertussis vaccine and tetanus, diphtheria, and aP vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Placebo and Boostrix
Description: Tetanus, diphtheria, and aP vaccine and placebo
Study: NCT06031415

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-0272
Description: Administered subcutaneously (for Part A) Administered intravenously or subcutaneously (for Part B)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-0272
Description: Administered subcutaneously (for Part A) Administered intravenously or subcutaneously (for Part B)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered subcutaneously (for Part A) Administered intravenously or subcutaneously (for Part B)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered subcutaneously (for Part A) Administered intravenously or subcutaneously (for Part B)
Study: NCT05124704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-8ml 0.375% ropivacaine
Description: 5-8ml of 0.375% ropivacaine depend on the height and weight of the patient was administrated through the epidural catheter at least 20 min before induction in experimental group. Followed by a continuous infusion of 4-6 ml/h using micro-infusion pump after induction during surgery.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: 5-8ml normal saline
Description: 5-8ml of normal saline depend on the height and weight of the patient was administrated through the epidural catheter at least 20 min before induction. Followed by a continuous infusion of 4-6 ml/h using micro-infusion pump after induction during surgery.
Study: NCT06099457

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SIB-Time web-application tool
Description: Parent-child dyads will use the SIBTime app in an 8-week intervention to test its relevance, acceptability, cultural appropriateness, and potential for efficacy.
Study: NCT05612880

Intervention type: DRUG
Intervention: androgen receptor signaling inhibitors
Description: Prior to or within 8 weeks of ARSI initiation, men with advanced prostate cancer will perform baseline testing, with follow ups at 12 and 24 weeks
Study: NCT05732792

Intervention type: OTHER
Intervention: CIPS Survey
Description: The survey is endorsed by the European Society of Anaesthesiology and Intensive Care (ESAIC) and will be distributed from February 2023 onwards to its members for a period of 3 months.~Each anesthesiologist's participation to the survey will be voluntary and anonymous individual consent will be implied by the person's willingness to complete the survey.~The survey will also mention this.~All surveys will be administered via SurveyMonkey. Surveymonkey allows to build Health Insurance Portability and Accountability Act (HIPAA) compliant surveys that follow strict rules around the protection of health information.~Of note, Surveymonkey is also GDPR (General Data Protection Regulation) compliant.~Data gathered from the questionnaires will be safely stored on the surveymonkey database. The access to the result database is held by a password that only the authors can use to analyze the data yielded at the end of the survey period.
Study: NCT05526846

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Plant-based diet education
Description: Participants will receive weekly emails with information about plant-based diets and a goal/task for each week.~There will be a 'core curriculum' that will be sent to all participants, as well as additional information according to the participant's stage of change and food choice preferences.~All information will be available on a website that will be created for this study. The website will feature curated information about plant-based diets, that is tailored to patients who had recent colorectal operations and may have a colostomy or an ileostomy.
Study: NCT05338918

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mental Imagery with Virtual Reality Training
Description: Mental Imagery TASK Practice with Virtual Reality Training: 30-40 minutes treatment sessions will be performed three times a week for six weeks, Part 1: 2-3 minutes of relaxation Part 2: Visual Imagery (external motor imagery training) for 5-8 minutes Part 3: Actual Task Practice for 10 minutes Part 4: Virtual Reality based training (including games for lower limb functions) for 10 minutes Part 5:Task Oriented training for 10 minutes Tasks for both (mental imagery + actual task practice) will be: Sit-stand task, Static stance (30 seconds), Indoor walk on a leveled surface, Walk indoor towards target, Forward / Side Stepping, Walking outdoors

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Virtual Reality Training
Description: Virtual Reality Training: 30-40 minutes treatment sessions will be performed three times a week for six weeks. Games will include River rush, 20000 water leaks, reflex ridge along with task oriented training. Tasks will be: Sit-stand task, Static stance (30 seconds), Indoor walk on a leveled surface, Walk indoor towards target, Forward / Side Stepping, Walking outdoors
Study: NCT05797233

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-CD19 and anti-CD20 bicistronic CAR T- cells
Description: 0.66x10\^6 CAR+ T - 10x10\^6 CAR+ T cells/kg (weight based dosing per cohort) infused on day 0

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-CD19 and anti-CD20 bicistronic CAR T- cells
Description: 0.66x10\^6 CAR+ T - 10x10\^6 CAR+ T cells/kg (weight based dosing per cohort) infused on day 0

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 500 mg/m\^2 IV infusion over 30 minutes on days -5, -4 and -3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 500 mg/m\^2 IV infusion over 30 minutes on days -5, -4 and -3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30 mg/m\^2 IV infusion over 30 minutes administered immediately following the cyclophosphamide on days -5, -4,and -3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30 mg/m\^2 IV infusion over 30 minutes administered immediately following the cyclophosphamide on days -5, -4,and -3
Study: NCT05935163

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional therapy for hamstring tightness
Description: Conventional Physical therapy will include TENS , hot pack , Hamstring self stretch , Calf self stretching , bridging exercise , piriformis stretch , prone on hands and prone on elbows.
Study: NCT05586516

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IOA-289
Description: IOA-289 will be administered orally twice daily (BID), starting from C0D1. Gemcitabine and nab-paclitaxel will be administrated by IV infusion, weekly for 3 weeks of a 4 week cycle starting at C1D1.
Study: NCT05935163

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional therapy for hamstring tightness
Description: Conventional Physical therapy will include TENS , hot pack , Hamstring self stretch , Calf self stretching , bridging exercise , piriformis stretch , prone on hands and prone on elbows.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bowen Technique
Description: Bowen Technique:~1. The patient will assume a full prone-lying position on the plinth.~2. Sequence of short gentle moves will be applied over hamstrings. Firstly, the thumbs will be placed on top of the hamstrings muscle and the tightness is assessed.~3. Then, the muscle will be hooked by the thumbs from its lateral edge. Then, gentle pressure will be applied to the point of resistance to challenge the muscle in medial direction, as the thumbs will be flattened in medial direction, the muscle will pluck under the thumbs.~4. First with the thumbs, then will be followed by the fingers. Often, the hands are placed with a distance of inch of space between the thumbs and fingers so that the hands performed the technique on the muscle easily.~5. The whole procedure will be repeated again. The treatment time for each session will be 20 minutes for each side.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dynamic Soft Tissue Mobilization (DSTM):
Description: 1. To access the hamstring muscle group, the subject will be asked to attain prone position and deep longitudinal strokes will be applied to the entire muscle group. Once the specific area of hamstring muscle tightness will be located, the remaining treatment will be limited to this target area.~2. To execute the dynamic intervention, the subject will be requested to move in the supine position with the hip and knee flexed to 90 degree.~3. Deep longitudinal strokes will be applied in a distal to proximal direction to the area of hamstring tightness and the leg will be passively moved to knee extension. Five strokes will be applied and 20 seconds of shaking is performed at the completion of this technique.~4. This treatment will be given for 20 minutes on each side.
Study: NCT04965155

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab-dexamethasone
Description: Isatuximab 10 mg/kg IV: 1,8,15 and 22 at cycle 1; days 1 and 15 at cycles 2-3 Dexamethasone 40 mg OS: 1,8,15 and 22 at cycle 1; days 1 and 15 at cycles 2-3
Study: NCT05573477

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ATB-1011
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATB-1011
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATB-1012
Description: Oral tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ATB-1012
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATB-1012
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATB-1013
Description: Oral tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ATB-1011 placebo
Description: Placebo matched to ATB-1011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATB-1011 placebo
Description: Placebo matched to ATB-1011

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ATB-1012 placebo
Description: Placebo matched to ATB-1012

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ATB-1013 placebo
Description: Placebo matched to ATB-1013
Study: NCT05097989

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN2050
Description: Oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN2050
Description: Oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN2050
Description: Oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN2050
Description: Oral tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablets
Study: NCT06016764

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Theta Burst in Transcranial Magnetic Stimulation
Description: This application will use a participant's own individual brain magnetic resonance image to target the primary motor strip with transcranial magnetic stimulation; to determine if hyper-excitability of the brain directly correlates with symptoms of catatonia, intellectual disability, and social-emotional impairment in autism